Benzinga · Sep 18, 2026
Canaccord Genuity Maintains Buy on Stryker, Lowers Price Target to $385
Canaccord Genuity analyst Kyle Rose maintains Stryker (NYSE:SYK) with a Buy and lowers the price target from $400 to $385.
NYSE · SYK
Stryker Corporation
Healthcare · Medical - Devices
$275.12
Down-$5.01 (-1.79%)
Updated Sep 20, 2026, 9:05 AM
SID Score
4.6/10
Composite research score
Smart Money
50/100
Neutral
- Market cap
- 134.97B
- P/E ratio
- 45.86
- Dividend yield
- 1.22%
- 52-week range
- $267.00 – $389.33
- Volume
- 4.81M
- Avg. volume
- 1.61M
Price performance
SYK price history
1M range · 19 trading sessions · Daily adjusted prices
SYK closed at $275.12 after 19 trading sessions, down 16.07% for the selected period.
- Last close
- $275.12
- Period change
- -16.07%
- Period low
- $270.01
- Period high
- $330.69
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $278.02 | $279.26 | $274.37 | $275.12 | 4.81M |
| Sep 17, 2026 | $286.10 | $286.125 | $279.09 | $280.13 | 2.37M |
| Sep 16, 2026 | $280.34 | $290.51 | $279.875 | $284.76 | 3.4M |
| Sep 15, 2026 | $281.00 | $282.69 | $277.62 | $281.50 | 3.46M |
| Sep 14, 2026 | $282.31 | $287.165 | $280.67 | $281.87 | 2.94M |
| Sep 11, 2026 | $270.72 | $277.00 | $267.00 | $275.56 | 3.72M |
| Sep 10, 2026 | $274.62 | $278.00 | $269.64 | $270.01 | 3.48M |
| Sep 9, 2026 | $271.835 | $278.745 | $270.85 | $275.39 | 5.5M |
| Sep 8, 2026 | $301.00 | $301.505 | $275.10 | $276.43 | 6.32M |
| Sep 4, 2026 | $304.49 | $307.545 | $302.51 | $303.13 | 2.4M |
| Sep 3, 2026 | $313.96 | $319.50 | $306.50 | $307.99 | 2.66M |
| Sep 2, 2026 | $315.06 | $321.745 | $311.38 | $312.19 | 2.19M |
| Sep 1, 2026 | $329.83 | $331.50 | $316.85 | $317.40 | 2.14M |
| Aug 31, 2026 | $327.79 | $329.50 | $323.12 | $323.80 | 2.04M |
| Aug 28, 2026 | $322.61 | $332.72 | $322.12 | $330.69 | 2.23M |
| Aug 27, 2026 | $326.845 | $328.4499 | $321.60 | $322.12 | 2.17M |
| Aug 26, 2026 | $329.13 | $333.39 | $326.41 | $329.67 | 1.57M |
| Aug 25, 2026 | $325.09 | $331.75 | $324.00 | $330.59 | 2.2M |
| Aug 24, 2026 | $330.00 | $334.87 | $327.01 | $327.81 | 1.88M |
Latest SYK news
The latest Smart Investors Daily articles mentioning SYK.
Stock researchCompany · Overview
SYK research
Overview
Company profile and research snapshot.
Company profile
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $419.33
- Implied upside
- —
- Analysts
- 18
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 18, 2026 | Canaccord Genuity | Buy | — |
| Sep 10, 2026 | Citigroup | Buy | — |
| Sep 9, 2026 | Wells Fargo | Overweight | — |
| Aug 13, 2026 | Wolfe Research | Peer Perform | — |
| Aug 3, 2026 | Citizens | Market Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 17, 2026
Stryker Facing Promising Setup Next Year, Trading Upside Limited in 2026, RBC Says
Stryker (SYK) will likely see an acceleration story in 2027, with high single digit growth achievabl
Yahoo · Sep 17, 2026
Stryker Expands Foot & Ankle Innovation With Prophecy and smartHEX
SYK expands its Foot & Ankle portfolio with Prophecy for Incompass and smartHEX, linking planning, implants and limb reconstruction.
Yahoo · Sep 16, 2026
GEHC or SYK: Which Is the Better Value Stock Right Now?
GEHC vs. SYK: Which Stock Is the Better Value Option?
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
